Certuity LLC Raises Stock Position in Eli Lilly and Company (NYSE:LLY)

Certuity LLC increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 319.3% in the 4th quarter, HoldingsChannel reports. The firm owned 9,933 shares of the company’s stock after acquiring an additional 7,564 shares during the quarter. Certuity LLC’s holdings in Eli Lilly and Company were worth $5,790,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in LLY. Lipe & Dalton purchased a new position in shares of Eli Lilly and Company during the fourth quarter worth $26,000. Thompson Investment Management Inc. purchased a new position in shares of Eli Lilly and Company during the third quarter worth $27,000. Legacy Financial Group LLC acquired a new stake in Eli Lilly and Company during the third quarter valued at $35,000. Optiver Holding B.V. acquired a new stake in Eli Lilly and Company during the third quarter valued at $36,000. Finally, Family CFO Inc acquired a new stake in Eli Lilly and Company during the third quarter valued at $40,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 6.0 %

LLY stock traded up $44.10 during trading on Tuesday, reaching $781.30. 5,419,168 shares of the stock were exchanged, compared to its average volume of 3,044,902. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The business has a 50 day moving average price of $760.89 and a 200-day moving average price of $668.00. Eli Lilly and Company has a 1 year low of $392.26 and a 1 year high of $800.78. The firm has a market capitalization of $742.36 billion, a price-to-earnings ratio of 134.43, a P/E/G ratio of 1.60 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. During the same period in the previous year, the firm earned $2.09 earnings per share. Eli Lilly and Company’s quarterly revenue was up 28.1% compared to the same quarter last year. On average, research analysts predict that Eli Lilly and Company will post 12.51 earnings per share for the current year.

Analysts Set New Price Targets

LLY has been the topic of several analyst reports. DZ Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target on the stock. in a research report on Wednesday, February 21st. Morgan Stanley lifted their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. Barclays lifted their target price on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research report on Wednesday, February 7th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 target price (up previously from $815.00) on shares of Eli Lilly and Company in a research report on Tuesday. Finally, Wells Fargo & Company lifted their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $731.55.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the sale, the insider now directly owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.